NTLA

Announcements

Nothing here yet

Daily updates

• Intellia Therapeutics is developing lonvoguran ziclumeran (lonvo-z), an investigational gene-editing therapy for hereditary angioedema.Oct 10, 2026
• FDA granted Priority Review to Intellia's lonvo-z BLA for hereditary angioedemaSep 8, 2026

FDA designations

Nothing here yet

News

• Intellia Therapeutics' BLA for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema was accepted by the FDA for Priority ReviewSep 8, 2026
• Intellia reported additional positive Phase 3 results for lonvo-z in hereditary angioedema patientsJun 15, 2026
• Intellia Therapeutics initiated rolling BLA submission to the FDA for lonvo-z as a one-time treatment for hereditary angioedemaApr 27, 2026
• Intellia Therapeutics reported that the FDA lifted the clinical hold on the MAGNITUDE Phase 3 trial in ATTR-CMMar 2, 2026
• Intellia Therapeutics received FDA lift of clinical hold on MAGNITUDE-2 Phase 3 trialJan 27, 2026